ASND vs MEDP

ASND's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow, while the absence of an Altman Z-Score raises concern about long-term solvency. Despite this, the company exhibits strong revenue growth (42.3% YoY) and a robust gross margin (86.82%), supported by a high analyst consensus of 'strong_buy' and a target price of $282.19. The stock trades at a premium valuation (Price/Sales: 19.27, Forward P/E: 17.77), reflecting market confidence in its growth trajectory rather than current profitability. Insider sentiment is neutral (40/100), suggesting cautious optimism, while technical trends remain bearish, indicating short-term weakness.

Medpace exhibits strong operational health with a Piotroski F-Score of 7/9 and an exceptional ROE of 70.23%, reflecting a high-efficiency growth engine. However, the stock is significantly overvalued from a defensive standpoint, trading at $501.23 against a Graham Number of $74.63 and slightly above its growth-based intrinsic value of $451.35. While revenue and earnings growth remain robust, the high PEG ratio (2.98) and aggressive insider selling by the CEO and President suggest the current price may have peaked. The overall profile is that of a high-quality company trading at a premium valuation.